Abiraterone Interactions
Acetylsalicylic acid
No clinically significant drug interactions identified.
Alendronate
No clinically significant drug interactions identified.
Allopurinol
No clinically significant drug interactions identified.
Alprazolam
No clinically significant drug interactions identified.
Amiodarone
No clinically significant drug interactions identified.
Amitriptyline
Caution - increased level of amitriptyline due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Amlodipine
No clinically significant drug interactions identified.
Amoxicillin
No clinically significant drug interactions identified.
Amoxicillin/clavulanate
No clinically significant drug interactions identified.
Amphetamine
Caution - increased level of amphetamine due to 2D6 inhibition. Monitor for signs of toxicity (ie. tachycardia, agitation, anxiety). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Apixaban
Caution - increased level of apixaban due to potential 3A4 inhibition. Consider choosing an alternative agent.
Aripiprazole (IM)
Avoid combination - increased level of aripiprazole due to 2D6 inhibiton. Long-acting IM depot formulations pose concern for toxicity (unable to rapidly withdraw agent if needed). Choose an alternative agent.
Aripiprazole (PO)
Caution - increased level of aripiprazole due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Empiric dose reduction by 25% recommended if used with concurrent 3A4 inhibitor. Low doses used as adjunct for major depressive disorder unlikely to cause clinical concern. Consider choosing an alternative agent for use in schizophrenia or bipolar disorder.
Atenolol
No clinically significant drug interactions identified.
Atomoxetine
Caution - increased level of atomoxetine due to 2D6 inhibition. Monitor for signs of toxicity (ie. tachycardia, agitation). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Atorvastatin
Caution - increased level of atorvastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction.
Azithromycin
No clinically significant drug interactions identified.
Baclofen
No clinically significant drug interactions identified.
Bisoprolol
No clinically significant drug interactions identified.
Buprenorphine/naloxone
No clinically significant drug interactions identified.
Bupropion
No clinically significant drug interactions identified.
Buspirone
No clinically significant drug interactions identified.
Calcium
No clinically significant drug interactions identified.
Canagliflozin
No clinically significant drug interactions identified.
Candesartan
No clinically significant drug interactions identified.
Carbamazepine
Avoid combination - decreased level of abiraterone due to 3A4 induction. Choose an alternative agent.
Carvedilol
Caution - increased level of carvedilol due to 2D6 inhibition. Monitor for signs of toxicity (ie. hypotension, bradycardia, impotence). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Cephalexin
No clinically significant drug interactions identified.
Cetirizine
No clinically significant drug interactions identified.
Chlorthalidone
No clinically significant drug interactions identified.
Cholecalciferol
No clinically significant drug interactions identified.
Ciprofloxacin
No clinically significant drug interactions identified.
Citalopram
No clinically significant drug interactions identified.
Clarithromycin
No clinically significant drug interactions identified.
Clindamycin
No clinically significant drug interactions identified.
Clomipramine
Caution - increased level of clomipramine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Clonazepam
No clinically significant drug interactions identified.
Clonidine
No clinically significant drug interactions identified.
Clopidogrel
No clinically significant drug interactions identified.
Codeine
Caution - decreased level of codeine due to 2D6 inhibition. CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Titrate with extreme caution due to risk of overdose. If already established on codeine, may require dose reduction. Consider choosing an alternative agent.
Colchicine
No clinically significant drug interactions identified.
Cyclobenzaprine
No clinically significant drug interactions identified.
Dabigatran
No clinically significant drug interactions identified.
Dapagliflozin
No clinically significant drug interactions identified.
Degarelix
No clinically significant drug interactions identified.
Denosumab
No clinically significant drug interactions identified.
Desipramine
Caution - increased level of desipramine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Desvenlafaxine
No clinically significant drug interactions identified.
Dexamethasone
No clinically significant drug interactions identified.
Dexlansoprazole
No clinically significant drug interactions identified.
Dextroamphetamine
Caution - increased level of dextroamphetamine due to 2D6 inhibition. Monitor for signs of toxicity (ie. tachycardia, agitation, anxiety). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Diazepam
No clinically significant drug interactions identified.
Diclofenac
No clinically significant drug interactions identified.
Digoxin
No clinically significant drug interactions identified.
Diltiazem
No clinically significant drug interactions identified.
Dimenhydrinate
No clinically significant drug interactions identified.
Divalproex
No clinically significant drug interactions identified.
Docusate
No clinically significant drug interactions identified.
Domperidone
No clinically significant drug interactions identified.
Donepezil
No clinically significant drug interactions identified.
Doxazosin
No clinically significant drug interactions identified.
Doxycycline
No clinically significant drug interactions identified.
Duloxetine
Caution - increased level of duloxetine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Dutasteride
No clinically significant drug interactions identified.
Edoxaban
No clinically significant drug interactions identified.
Eletriptan
No clinically significant drug interactions identified.
Empagliflozin
No clinically significant drug interactions identified.
Enalapril
No clinically significant drug interactions identified.
Escitalopram
No clinically significant drug interactions identified.
Esomeprazole
No clinically significant drug interactions identified.
Ezetimibe
No clinically significant drug interactions identified.
Famotidine
No clinically significant drug interactions identified.
Fenofibrate
No clinically significant drug interactions identified.
Finasteride
No clinically significant drug interactions identified.
Fluconazole
No clinically significant drug interactions identified.
Fluoxetine
No clinically significant drug interactions identified.
Folic acid
No clinically significant drug interactions identified.
Fosfomycin
No clinically significant drug interactions identified.
Furosemide
No clinically significant drug interactions identified.
Gabapentin
No clinically significant drug interactions identified.
Galantamine
No clinically significant drug interactions identified.
Gliclazide
No clinically significant drug interactions identified.
Glyburide
No clinically significant drug interactions identified.
Goserelin
No clinically significant drug interactions identified.
Guanfacine
No clinically significant drug interactions identified.
Hydralazine
No clinically significant drug interactions identified.
Hydrochlorothiazide
No clinically significant drug interactions identified.
Hydromorphone
No clinically significant drug interactions identified.
Hydroxychloroquine
No clinically significant drug interactions identified.
Hydroxyzine
No clinically significant drug interactions identified.
Ibuprofen
No clinically significant drug interactions identified.
Indapamide
No clinically significant drug interactions identified.
Indomethacin
No clinically significant drug interactions identified.
Irbesartan
No clinically significant drug interactions identified.
Isotretinoin
No clinically significant drug interactions identified.
Itraconazole
No clinically significant drug interactions identified.
Ketorolac
No clinically significant drug interactions identified.
Labetalol
No clinically significant drug interactions identified.
Lansoprazole
No clinically significant drug interactions identified.
Leuprolide
No clinically significant drug interactions identified.
